Draper MW - Search Results

1

A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.

Geiser AG, Hummel CW, Draper MW, Henck JW, Cohen IR, Rudmann DG, Donnelly KB, Adrian MD, Shepherd TA, Wallace OB, McCann DJ, Oldham SW, Bryant HU, Sato M, Dodge JA. Geiser AG, et al. Among authors: draper mw. Endocrinology. 2005 Oct;146(10):4524-35. doi: 10.1210/en.2005-0024. Epub 2005 Jul 7. Endocrinology. 2005. PMID: 16002528

2

Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.

Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, Magee DE, Termine JD, Bryant HU. Fuchs-Young R, et al. Among authors: draper mw. Ann N Y Acad Sci. 1995 Jun 12;761:355-60. doi: 10.1111/j.1749-6632.1995.tb31392.x. Ann N Y Acad Sci. 1995. PMID: 7625735 No abstract available.

3

Selective estrogen receptor modulators and postmenopausal women's health.

Hol T, Cox MB, Bryant HU, Draper MW. Hol T, et al. Among authors: draper mw. J Womens Health. 1997 Oct;6(5):523-31. doi: 10.1089/jwh.1997.6.523. J Womens Health. 1997. PMID: 9356975 Review.

4

Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles.

Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB. Baker VL, et al. J Clin Endocrinol Metab. 1998 Jan;83(1):6-13. doi: 10.1210/jcem.83.1.4448. J Clin Endocrinol Metab. 1998. PMID: 9435408 Clinical Trial.

5

The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.

Draper MW. Draper MW. Ann N Y Acad Sci. 2003 Nov;997:373-7. doi: 10.1196/annals.1290.040. Ann N Y Acad Sci. 2003. PMID: 14644844 Review.

6

Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators.

Draper MW, Chin WW. Draper MW, et al. Clin Obstet Gynecol. 2003 Jun;46(2):265-97. doi: 10.1097/00003081-200306000-00008. Clin Obstet Gynecol. 2003. PMID: 12808380 Review. No abstract available.

7

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.

Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Boss SM, et al. Among authors: draper mw. Am J Obstet Gynecol. 1997 Dec;177(6):1458-64. doi: 10.1016/s0002-9378(97)70091-7. Am J Obstet Gynecol. 1997. PMID: 9423751 Clinical Trial.

8

Antiestrogenic properties of raloxifene.

Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Draper MW, et al. Pharmacology. 1995 Apr;50(4):209-17. doi: 10.1159/000139284. Pharmacology. 1995. PMID: 7792309 Clinical Trial.

9

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.

Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. Draper MW, et al. J Bone Miner Res. 1996 Jun;11(6):835-42. doi: 10.1002/jbmr.5650110615. J Bone Miner Res. 1996. PMID: 8725181 Clinical Trial.

10

Raloxifene and estrogen: comparative bone-remodeling kinetics.

Heaney RP, Draper MW. Heaney RP, et al. Among authors: draper mw. J Clin Endocrinol Metab. 1997 Oct;82(10):3425-9. doi: 10.1210/jcem.82.10.4322. J Clin Endocrinol Metab. 1997. PMID: 9329380 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters